Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH
Top

09-12-2015 | Osteoporosis | Review | Article

Bisphosphonate Treatment in Osteoporosis: Optimal Duration of Therapy and the Incorporation of a Drug Holiday

Journal: HSS Journal ®

Authors: Jordan C. Villa, MD, Arianna Gianakos, BS, Joseph M. Lane, MD

Publisher: Springer US

Login to get access

Abstract

Background

Bisphosphonates are the most widely used treatment for osteoporosis. They accumulate in the bone for years, and therefore, their inhibitory effects on osteoclasts may persist after drug discontinuation. The ideal duration of therapy remains controversial.

Questions/Purposes

The purpose of this study is to review the literature to determine the (1) indications for drug holiday, (2) the duration of drug holiday, (3) the evaluation during drug holiday, and (4) the proper treatment and maintenance after drug holiday.

Methods

A review of two electronic databases (PubMed/MEDLINE and EMBASE) was conducted using the term “(Drug holiday),” in January 29, 2015. Inclusion criteria were as follows: (1) clinical trials and case control, (2) human studies, (3) published in a peer-review journal, and (4) written in English. Exclusion criteria were as follows: (1) case reports, (2) case series, and (3) in vitro studies.

Results

The literature supports a therapeutic pause after 3–5 years of bisphosphonate treatment in patients with minor bone deficiencies and no recent fragility fracture (low risk) and in patients with moderate bone deficiencies and/or recent fragility fracture (moderate risk). In these patients, a bone health reevaluation is recommended every 1–3 years. Patients with high fracture risk should be maintained on bisphosphonate therapy without drug holiday.

Conclusion

The duration and length of drug holiday should be individualized for each patient. Evaluation should be based on serial bone mass measurements, bone turnover rates, and fracture history evaluation. If after drug therapy, assessments show an increased risk of fracture, the patient may benefit from initiating another treatment. Raloxifene, teriparatide, or denosumab are available options.
Literature
1.
Abrahamsen B, Eiken P, Eastell R. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009; 360(17): 1789. author reply 1791-2.CrossRefPubMed
2.
Anastasilakis AD, Polyzos SA, Gkiomisi A, Bisbinas I, Gerou S, Makras P. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial. J Clin Endocrinol Metab. 2013; 98(8): 3206-3212.CrossRefPubMed
3.
Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ. Continuing bisphosphonate treatment for osteoporosis--for whom and for how long? N Engl J Med. 2012; 366(22): 2051-2053.PubMedCentralCrossRefPubMed
4.
Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348(9041): 1535-1541.CrossRefPubMed
5.
Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356(18): 1809-1822.CrossRefPubMed
6.
Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-pivotal fracture trial (PFT). J Bone Miner Res. 2012; 27(2): 243-254.PubMedCentralCrossRefPubMed
7.
Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA. 2006; 296(24): 2927-2938.CrossRefPubMed
8.
Bone HG, Hosking D, Devogelaer JP, et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004; 350(12): 1189-1199.CrossRefPubMed
9.
Bonnick SL. HSA: beyond BMD with DXA. Bone. 2007; 41(1 Suppl 1): S9-12.PubMed
10.
Bonnick SL. Osteoporosis in men and women. Clin Cornerstone. 2006; 8(1): 28-39.CrossRefPubMed
11.
Bonnick SL, Johnston CC Jr, Kleerekoper M, et al. Importance of precision in bone density measurements. J Clin Densitom. 2001; 4(2): 105-110.CrossRefPubMed
12.
Bonnick SL, Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med. 2006; 119(4 Suppl 1): S25-31.CrossRefPubMed
13.
Cardwell CR, Abnet CC, Cantwell MM, Murray LJ. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA. 2010; 304(6): 657-663.PubMedCentralCrossRefPubMed
14.
Cartsos VM, Zhu S, Zavras AI. Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people. J Am Dent Assoc. 2008; 139(1): 23-30.CrossRefPubMed
15.
Chapurlat RD, Palermo L, Ramsay P, Cummings SR. Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. Osteoporos Int. 2005; 16(7): 842-848.CrossRefPubMed
16.
Chiha M, Myers LE, Ball CA, Sinacore JM, Camacho PM. Long-term follow-up of patients on drug holiday from bisphosphonates: real-world setting. Endocr Pract. 2013; 19(6): 989-994.CrossRefPubMed
17.
Compston JE, Bilezikian JP. Bisphosphonate therapy for osteoporosis: the long and short of it. J Bone Miner Res. 2012; 27(2): 240-242.CrossRefPubMed
18.
Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014; 25(10): 2359-2381.PubMedCentralCrossRefPubMed
19.
Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA. 1998; 280(24): 2077-2082.CrossRefPubMed
20.
Curtis JR, Westfall AO, Cheng H, Delzell E, Saag KG. Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int. 2008; 19(11): 1613-1620.PubMedCentralCrossRefPubMed
21.
Dell RM, Adams AL, Greene DF, et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res. 2012; 27(12): 2544-2550.CrossRefPubMed
22.
Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008; 83(9): 1032-1045.PubMedCentralCrossRefPubMed
23.
Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) investigators. JAMA. 1999; 282(7): 637-645.CrossRefPubMed
24.
Farooki A. NCCN bone health task force: key recommendations. J Natl Compr Cancer Netw. 2014; 12(5 Suppl): 813-816.
25.
Fliefel R, Troltzsch M, Kuhnisch J, Ehrenfeld M, Otto S. Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: A systematic review. Int J Oral Maxillofac Surg. 2015.
26.
Freemantle N, Satram-Hoang S, Tang ET, et al. Final results of the DAPS (denosumab adherence preference satisfaction) study: A 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int. 2012; 23(1): 317-326.PubMedCentralCrossRefPubMed
27.
Gedmintas L, Solomon DH, Kim SC. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res. 2013; 28(8): 1729-1737.PubMedCentralCrossRefPubMed
28.
Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ. 2010; 341: c4444.PubMedCentralCrossRefPubMed
29.
Harris ST, Watts NB, Genant HK, et al. Effects of Risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral efficacy with Risedronate therapy (VERT) study group. JAMA. 1999; 282(14): 1344-1352.CrossRefPubMed
30.
Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab. 2002; 87(4): 1586-1592.CrossRefPubMed
31.
Inoue G, Ueno M, Nakazawa T, et al. Teriparatide increases the insertional torque of pedicle screws during fusion surgery in patients with postmenopausal osteoporosis. J Neurosurg Spine. 2014; 21(3): 425-431.CrossRefPubMed
32.
Komm BS, Chines AA. An update on selective estrogen receptor modulators for the prevention and treatment of osteoporosis. Maturitas. 2012; 71(3): 221-226.CrossRefPubMed
33.
Kwon YD, Lee DW, Choi BJ, Lee JW, Kim DY. Short-term teriparatide therapy as an adjunctive modality for bisphosphonate-related osteonecrosis of the jaws. Osteoporos Int. 2012; 23(11): 2721-2725.CrossRefPubMed
34.
Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996; 18(2): 75-85.CrossRefPubMed
35.
Lo JC, O’Ryan FS, Gordon NP, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg. 2010; 68(2): 243-253.CrossRefPubMed
36.
McClung M, Harris ST, Miller PD, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med. 2013; 126(1): 13-20.CrossRefPubMed
37.
McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. hip intervention program study group. N Engl J Med. 2001; 344(5): 333-340.CrossRefPubMed
38.
McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006; 354(8): 821-831.CrossRefPubMed
39.
McNabb B, Vittinghoff E, Eastell R, et al. A model of BMD changes after alendronate discontinuation to guide postalendronate BMD monitoring. J Clin Endocrinol Metab. 2014; 99(11): 4094-4100.CrossRefPubMed
40.
Mellstrom DD, Sorensen OH, Goemaere S, Roux C, Johnson TD, Chines AA. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int. 2004; 75(6): 462-468.CrossRefPubMed
41.
Moeney D. Briefing information for the September 9, 2011 joint meeting of the advisory. Committee for Reproductive Health Drugs and the Drug Safety and Risk. Management Advisory Committee. 2011;Appendix 8.
42.
Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344(19): 1434-1441.CrossRefPubMed
43.
Ohtori S, Inoue G, Orita S, et al. Comparison of teriparatide and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spinal fusion surgery in postmenopausal women with osteoporosis from a bone quality perspective. Spine (Phila Pa 1976). 2013; 38(8): E487-92.CrossRef
44.
Pazianas M, van der Geest S, Miller P. Bisphosphonates and bone quality. Bonekey Rep. 2014; 3: 529.PubMedCentralCrossRefPubMed
45.
Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. vertebral efficacy with risedronate therapy (VERT) study group. Osteoporos Int. 2000; 11(1): 83-91.CrossRefPubMed
46.
Rizzoli R, Reginster JY, Boonen S, et al. Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int. 2011; 89(2): 91-104.PubMedCentralCrossRefPubMed
47.
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA. 2002; 288(3): 321-333.CrossRefPubMed
48.
Roux C, Hofbauer LC, Ho PR, et al. Denosumab compared with Risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone. 2014; 58: 48-54.CrossRefPubMed
49.
Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007; 357(20): 2028-2039.CrossRefPubMed
50.
Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011; 364(18): 1728-1737.CrossRefPubMed
51.
Schmidt GA, Horner KE, McDanel DL, Ross MB, Moores KG. Risks and benefits of long-term bisphosphonate therapy. Am J Health Syst Pharm. 2010; 67(12): 994-1001.CrossRefPubMed
52.
Schwartz AV, Bauer DC, Cummings SR, et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res. 2010; 25(5): 976-982.CrossRefPubMed
53.
Schwartz AV, Garnero P, Hillier TA, et al. Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab. 2009; 94(7): 2380-2386.PubMedCentralCrossRefPubMed
54.
Sebba A. Osteoporosis: how long should we treat? Curr Opin Endocrinol Diabetes Obes. 2008; 15(6): 502-507.CrossRefPubMed
55.
Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014; 29(1): 1-23.CrossRefPubMed
56.
Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010; 25(11): 2267-2294.CrossRefPubMed
57.
Silverman SL, Cummings SR, Watts NB. Consensus panel of the ASBMR, ISCD, and NOF. Recommendations for the clinical evaluation of agents for treatment of osteoporosis: consensus of an expert panel representing the American Society for Bone and Mineral Research (ASBMR), the International Society for Clinical Densitometry (ISCD), and the National Osteoporosis Foundation (NOF). J Bone Miner Res. 2008; 23(1): 159-165.CrossRefPubMed
58.
Sorensen OH, Crawford GM, Mulder H, et al. Long-term efficacy of Risedronate: a 5-year placebo-controlled clinical experience. Bone. 2003; 32(2): 120-126.CrossRefPubMed
59.
Thumbigere-Math V, Sabino MC, Gopalakrishnan R, et al. Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients. J Oral Maxillofac Surg. 2009; 67(9): 1904-1913.CrossRefPubMed
60.
Vestergaard P, Schwartz F, Rejnmark L, Mosekilde L. Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene. Osteoporos Int. 2011; 22(3): 993-1001.CrossRefPubMed
61.
Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab. 2000; 85(1): 231-236.CrossRefPubMed
62.
Watts NB, Chines A, Olszynski WP, et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int. 2008; 19(3): 365-372.CrossRefPubMed
63.
Wilkinson GS, Kuo YF, Freeman JL, Goodwin JS. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst. 2007; 99(13): 1016-1024.CrossRefPubMed
64.
Wysowski DK, Greene P. Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the united states, 2002-2012. Bone. 2013; 57(2): 423-428.CrossRefPubMed
65.
Zavras AI, Zhu S. Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis? J Oral Maxillofac Surg. 2006; 64(6): 917-923.CrossRefPubMed
Image Credits